US FDA Approves BeiGene Tislelizumab Combo for HER2-Positive Gastroesophageal Cancer
The US Food and Drug Administration has approved BeiGene's supplemental biologics license application for BeiZhan (tislelizumab), covering a new indication for use in combination with BeiHe'an (zanidatamab) and chemotherapy as first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.
The approval, based on data from the relevant clinical study, provides a new treatment option for this patient population. BeiGene announced the news on August 26.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 30/100 and 80% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.